Entropy Technologies LP Sells 17,004 Shares of Edwards Lifesciences Co. (NYSE:EW)

Entropy Technologies LP reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 54.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,344 shares of the medical research company’s stock after selling 17,004 shares during the quarter. Entropy Technologies LP’s holdings in Edwards Lifesciences were worth $1,062,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $30,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the period. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $46,000. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,000 shares of company stock valued at $547,430. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 1.0 %

EW opened at $71.05 on Tuesday. The stock has a market capitalization of $41.91 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 3.64 and a beta of 1.10. The firm has a 50 day moving average price of $72.45 and a 200-day moving average price of $69.18. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Analyst Ratings Changes

A number of equities analysts have issued reports on EW shares. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. The Goldman Sachs Group increased their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Barclays boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Robert W. Baird dropped their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and an average price target of $79.19.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.